Insights Into Renal Cell Carcinoma (RCC)
Perspectives on drivers in treatment decisions in the management of RCC
Southeast/FL – February 10, 2022
Faculty Chair
Daniel J. George, MD
Duke Cancer Center
Central – February 21, 2022
Faculty Chair
Ulka Vaishampayan, MD
Karmanos Cancer Center
Southwest #1 – February 23, 2022
Faculty Chair
Rana McKay, MD
UC San Diego Medical Center
MI, OH – April 12, 2022
Faculty Chair
Stephanie Berg, MD
Loyola University Medical Center
CA, AZ, NM, NV – April 28, 2022
Faculty Chair
Sumanta Pal, MD
City of Hope Comprehensive Cancer Center
Northeast – June 21, 2022
Faculty Chair
David Braun, MD, PhD
Dana-Farber Cancer Center
More Information
- Virtual series
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Virtual series
- Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana
More Information
- Virtual series
- Southern California, Nevada, Utah, Arizona, New Mexico, Colorado
More Information
- Virtual series
- National
More Information
- Virtual series
- Colorado, Iowa, Oregon
More Information
- Virtual series
- California, Arizona, Nevada, and New Mexico
More Information
- Virtual series
- Connecticut, Delaware, DC, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
More Information
- Virtual series
- Minnesota, Illinois
More Information
- Virtual series
- Southern California, Nevada, Utah, Arizona, New Mexico, Colorado
More Information
- Virtual series
- Illinois, Iowa, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio
More Information
- Virtual series
- Northern California, Oregon, Washington, Idaho, Montana, Wyoming
REPORT SNAPSHOT
- A virtual, moderated roundtable discussion focusing on the treatment of RCC
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained: sunitinib, pazopanib, cabozantinib, axitinib, lenvatinib, ipilimumab, pembrolizumab, nivolumab, avelumab, everolimus, and combinations of these drugs
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region
